Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

39.73 -0.11 (-0.28%)
Streaming Delayed Price Updated: 12:07 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
News headline image
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
One fast-growing digital health stock just secured a notable new backer—right as its financial momentum hits a fresh gear. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years. 
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Soleno just turned profitable for the first time—right as a major fund made its move. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
CG Oncology Announces New Board Member and Board Transition
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting
Two late-breaking podium presentations and three posters continue to demonstrate cretostimogene as a potential backbone therapy for a broad range of NMIBC patients 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Why Cg Oncology Stock Rocketed 7% Higher Today ↗
One pundit believes this is a clinical-stage company well worth watching. 
Via The Motley Fool
News headline image
CG Oncology Stock Signals Bullish Momentum Ahead ↗
CG Oncology has entered its Phase 2 of the Adhishthana Cycle, signaling a bullish setup. With momentum already building, here's what to track... 
Via Benzinga
News headline image
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Completes Enrollment in PIVOT-006
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Cg Oncology (CGON) Q2 Loss Widens 93% ↗
Via The Motley Fool
News headline image
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Which stocks are moving before the opening bell on Tuesday? ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock ↗
 
Via Benzinga
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
News headline image
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
News headline image
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Issued on behalf of Oncolytics Biotech Inc. Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer.... 
Via FinancialNewsMedia
News headline image
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.